Patent · US Active

2,3-dihydroimidazo[1, 2-c] pyrimidin-5(1 H)-one compounds use as LP-PLA2 inhibitors

US8975400B2 · kind B2 · utility

2Cited by

0References

14Claims

0Family size

Assignee

Glaxo Group Limited · GB

Inventors

Zehong Wan · King of Prussia, US
Kai Long · Shanghai, CN
Yingxia Sang · Shanghai, CN
Xiaobo Su · Shanghai, CN

Key dates

Filing date	Jul 25, 2012
Grant date	Mar 10, 2015
Priority date	—
Expiry date	Jul 25, 2032

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P25/28
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Disclosed are 2,3-dihydroimiazo[1,2-c]pyrimidin-5(IH)-one compounds that inhibit Lp-PLA2,processes for their preparation, compositions containing them and their use in the treatment of diseases associated with the activity of Lp-PLA2, for example atherosclerosis, Alzheimer's disease.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.